Drug intelligence / Profile preview

HSF1 activator

Development stage: Preclinical
Lead developer: Sisu Pharma
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Sisu Pharma is developing a small-molecule activator of Heat Shock Factor 1 (HSF1) for the treatment of neurodegenerative conditions. Utilizing the company's proprietary HI-LiTe (HSF1-Interacting-Ligand Technology) platform, this program aims to enhance the cellular heat-shock response and increase the expression of chaperone proteins. By boosting protein-folding capacity, the activator is intended to provide neuroprotective effects against the protein misfolding and aggregation characteristic of neurodegenerative diseases. This approach contrasts with Sisu's oncology pipeline, which focuses on HSF1 degradation to treat solid tumors and hematological malignancies.

Other names: HSF1 activatorHSF-1 activatorHSF 1 activatorHI-LiTe HSF1 activator

Targets

HSF1 (Heat shock factor protein 1)

Beyond the preview

Go deeper on HSF1 activator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSF1 activator.

Explore the full profile